Therapeutic advances in pancreatic cancer

Gastroenterology

Volumn 144, Issue 6, 2013, Pages 1316-1326

  Paulson, Andrew Scott ^a   Tran Cao, Hop S ^b   Tempero, Margaret A ^a   Lowy, Andrew M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant Therapy; Chemotherapy; Pancreatic Cancer

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DIARRHEA; DISEASE FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LAPAROSCOPIC SURGERY; MINIMALLY INVASIVE SURGERY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ROBOTICS; SIGNAL TRANSDUCTION; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 84876805063     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.01.078     Document Type: Article

References (85)

1. M. Gagner, A. Pomp Laparoscopic pylorus-preserving pancreatoduodenectomy Surg Endosc 8 1994 408 410
2. A. Cushieri Laparoscopic surgery of the pancreas J R Coll Surg Edinb 39 1994 178 184
3. R. Venkat, B.H. Edil, R.D. Schulick Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis Ann Surg 255 2012 1048 1059
4. J. Winer, M.F. Can, D.L. Barlett The current state of robotic-assisted pancreatic surgery Nat Rev Gastroenterol Hepatol 9 2012 468 476
5. L. Fernández-Cruz, R. Cosa, L. Blanco Curative laparoscopic resection for pancreatic neoplasms: a critical analysis from a single institution J Gastrointest Surg 11 2007 1607 1621
6. D.A. Kooby, W.G. Hawkins, C.M. Schmidt A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg 210 2010 779 785
7. M. Daouadi, A.H. Zureikat, M.S. Zenati Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique Ann Surg 257 2013 128 132
8. J.L. Dulucq, P. Wintringer, A. Mahajna Laparoscopic pancreaticoduodenectomy for benign and malignant diseases Surg Endosc 20 2006 1045 1050
9. M.L. Kendrick, D. Cusati Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience Arch Surg 145 2010 19 23
10. C. Palanivelu, P.S. Rajan, M. Rangarajan Evolution in techniques of laparoscopic pancreaticoduodenectomy: a decade long experience from a tertiary center J Hepatobiliary Pancreat Surg 16 2009 731 740
11. P.C. Giulianotti, F. Sbrana, F.M. Bianco Robot-assisted laparoscopic pancreatic surgery: single-surgeon experience Surg Endosc 24 2010 1646 1657
12. H.J. Zeh, A.H. Zureikat, A. Secrest Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions Ann Surg Oncol 19 2012 864 870
13. J.L. Cameron, D.W. Crist, J.V. Sitzmann Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer Am J Surg 161 1991 120 124
14. M.H. Kalser, S.S. Ellenberg Pancreatic cancer Adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 1985 899 903
15. J.H. Klinkenbijl, J. Jeekel, T. Sahmoud Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776 782
16. J.P. Neoptolemos, D.D. Stocken, H. Friess A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210
17. H. Oettle, S. Post, P. Neuhuas Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277
18. J.P. Neoptolemos, M.J. Moore, T.F. Cox Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic resection: a randomized controlled trial JAMA 304 2010 1073 1081
19. W.F. Regine, K.A. Winter, R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 2008 1019 1026
20. C.C. Hsu, J.M. Herman, M.M. Corsini Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study Ann Surg Oncol 17 2010 981 990
21. V.J. Picozzi, R.A. Abrams, P.A. Decker Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031 Ann Oncol 22 2011 348 354
22. D.B. Evans, T.A. Rich, D.R. Byrd Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg 127 1992 1335 1339
23. P.W. Pisters, J.L. Abbruzzese, N.A. Janjan Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma J Clin Oncol 16 1998 3843 3850
24. P.W. Pisters, R.A. Wolff, N.A. Janjan Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome J Clin Oncol 20 2002 2537 2544
25. D.B. Evans, G.R. Varadhachary, C.H. Crane Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 2008 3496 3502
26. G.R. Varadhachary, R.A. Wolff, C.H. Crane Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 2008 3487 3495
27. J.S. Estrella, A. Rashid, J.B. Fleming Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation Cancer 118 2012 268 277
28. G.R. Varadhachary, E.P. Tamm, J.L. Abbruzzese Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy Ann Surg Oncol 13 2006 1035 1046
29. M.P. Callery, K.J. Chang, E.K. Fishman Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement Ann Surg Oncol 16 2009 1727 1733
30. M.H.G. Katz, P.W. Pisters, D.B. Evans Borderline resectable pancreatic cancer: the importance of this emerging stage of disease J Am Coll Surg 206 2008 833 846
31. M.H.G. Katz, J.B. Fleming, P. Bhosale Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators Cancer 118 2012 5749 5750
32. R. Siegel, D. Naishadham, A. Jemal Cancer statistics 2012 CA Cancer J Clin 62 2012 10 29
33. Y.H. Shaib, J.A. Davila, H.S. El-Serag The epidemiology of pancreatic cancer in the United States: changes below the surface Aliment Pharmacol Ther 24 2006 87 94
34. F. Huguet, N. Girard, C.S. Guerche Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review J Clin Oncol 27 2009 2269 2277
35. H.A. Burris 3rd, M.J. Moore, J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
36. G.P. Stathopoulos, K. Syrigos, G. Aravantinos A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Br J Cancer 95 2006 587 592
37. J.D. Berlin, P. Catalano, J.P. Thomas Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
38. V. Heinemann, D. Quietzsch, F. Gieseler Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 2006 3946 3952
39. G. Colucci, R. Labianca, F. Di Costanzo Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study J Clin Oncol 28 2010 1645 1651
40. C. Louvet, R. Labianca, P. Hammel Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 2005 3509 3516
41. E. Poplin, Y. Feng, J. Berlin Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 2009 3778 3785
42. R. Herrmann, G. Bodoky, J. Ruhstaller Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2007 2212 2217
43. D. Cunningham, I. Chau, D.D. Stocken Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 2009 5513 5518
44. A. Sultana, C. Tudur Smith, D. Cunningham Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy Br J Cancer 96 2007 1183 1190
45. V. Heinemann, S. Boeck, A. Hinke Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 2008 82
46. G.R. Oliver, E. Sugar, D. Laheru Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma ASCO Gastrointestinal Cancers Symposium 2010
47. D.D. Von Hoff, R.K. Ramanathan, M.J. Borad Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J Clin Oncol 29 2011 4548 4554
48. A. De Jesus-Acosta, G.R. Oliver, A. Blackford A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma Cancer Chemother Pharmacol 69 2012 415 424
49. R.L. Fine, D.R. Fogelman, S.M. Schreibman The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis Cancer Chemother Pharmacol 61 2008 167 175
50. National Comprehensive Cancer Network (NCCN) Guidelines: Pancreatic Adenocarcinoma Version 2.2012 www.nccn.org Accessed September 22, 2012
51. M. Tempero, W. Plunkett, V. Ruiz Van Haperen Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3402 3408
52. E. Giovannetti, M. Del Tacca, V. Mey Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res 66 2006 3928 3935
53. J. Spratlin, R. Sangha, D. Glubrecht The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res 10 2004 6956 6961
54. J.J. Farrell, H. Elsaleh, M. Garcia Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 2009 187 195
55. US National Institutes of Health ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world clinicaltrials.gov Accessed September 22, 2012
56. H.Q. Xiong, G.R. Varadhachary, J.C. Blais Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer Cancer 113 2008 2046 2052
57. U. Pelzer, I. Schwaner, J. Stieler Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group Eur J Cancer 47 2011 1676 1681
58. T. Conroy, B. Paillot, E. François Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study J Clin Oncol 23 2005 1228 1236
59. A.H. Ko FOLFIRINOX: a small step or a great leap forward? J Clin Oncol 29 2011 3727 3729
60. D. Matthaios, P. Zarogoulidis, I. Balgouranidou Molecular pathogenesis of pancreatic cancer and clinical perspectives Oncology 81 2011 259 272
61. M.J. Moore, D. Goldstein, J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
62. R.A. Miksad, L. Schnipper, M. Goldstein Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25 2007 4506 4507 author reply 4508
63. P.A. Philip, J. Benedetti, C.L. Corless Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 J Clin Oncol 28 2010 3605 3610
64. E. Van Cutsem, W.L. Vervenne, J. Bennouna Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 2009 2231 2237
65. H.L. Kindler, D. Niedzwiecki, D. Hollis Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) J Clin Oncol 28 2010 3617 3622
66. H.L. Kindler, T. Ioka, D.J. Richel Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study Lancet Oncol 12 2011 256 262
67. A.B. El-Khoueiry, R.K. Ramanathan, D.Y. Yang A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer Invest New Drugs 30 2012 1175 1183
68. Riess HEA. Double-Blind, Placebo-Controlled Randomized Phase III Trial of Aflibercept (A) Plus Gemcitabine (G) versus Placebo (P) Plus Gemcitabine (G) in Patients With Metastatic Pancreatic Cancer: Final Results. 12th World Congress on Gastrointestinal Cancer 2010, Barcelona, Spain.
69. M. Lohr, G. Klöppel, P. Maisonneuve Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis Neoplasia 7 2005 17 23
70. S. Gysin, M. Salt, A. Young Therapeutic strategies for targeting ras proteins Genes Cancer 2 2011 359 372
71. E. Van Cutsem, H. van de Velde, P. Karasek Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
72. G. Bodoky, C. Timcheva, D.R. Spigel A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Invest New Drugs 30 2012 1216 1223
73. M. Hidalgo Pancreatic cancer N Engl J Med 362 2010 1605 1617
74. P.P. Provenzano, C. Cuevas, A.E. Chang Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma Cancer Cell 21 2012 418 429
75. K.P. Olive, M.A. Jacobetz, C.J. Davidson Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 5933 2009 1457 1461
76. P.J. Loehrer Sr, Y. Feng, H. Cardenes Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial J Clin Oncol 29 2011 4105 4112
77. B. Chauffert, F. Mornex, F. Bonnetain Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer Definitive results of the 2000-01 FFCD/SFRO study Ann Oncol 19 2008 1592 1599
78. F. Huguet, T. André, P. Hammel Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies J Clin Oncol 25 2007 326 331
79. S. Krishnan, V. Rana, N.A. Janjan Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy Cancer 110 2007 47 55
80. A.H. Ko, J.M. Quivey, A.P. Venook A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 68 2007 809 816
81. R.D. Hofheinz, F. Wenz, S. Post Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial Lancet Oncol 13 2012 579 588
82. B.J. Schneider, E. Ben-Josef, C.J. McGinn Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer Int J Radiat Oncol Biol Phys 63 2005 1325 1330
83. J.B. Stokes, N.J. Nolan, E.B. Stelow Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer Ann Surg Oncol 18 2011 619 627
84. T. Rich, J. Harris, R. Abrams Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12 Am J Clin Oncol 27 2004 51 56
85. C.A. Iacobuzio-Donahue, B. Fu, S. Yachida DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813